A Randomized, Controlled Phase III Trial of Picoplatin and BSC Versus BSC Alone in Patients With Small Cell Lung Cancer (SCLC), Refractory or Progressive Within Six Months of Completing First-Line, Platinum-Containing Chemotherapy.

Trial Profile

A Randomized, Controlled Phase III Trial of Picoplatin and BSC Versus BSC Alone in Patients With Small Cell Lung Cancer (SCLC), Refractory or Progressive Within Six Months of Completing First-Line, Platinum-Containing Chemotherapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2012

At a glance

  • Drugs Picoplatin (Primary)
  • Indications Small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms SPEAR
  • Most Recent Events

    • 17 Mar 2012 Actual end date (Mar 2010) added as reported by European Clinical Trials Database record.
    • 17 Mar 2012 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
    • 08 Jun 2010 Final results presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO-2010), and in a Poinard media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top